Danaher (NYSE:DHR) PT Raised to $290.00

Danaher (NYSE:DHR) had its price target raised by research analysts at TD Cowen from $280.00 to $290.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the conglomerate’s stock. TD Cowen’s price objective would indicate a potential upside of 17.97% from the stock’s previous close.

Several other research analysts also recently commented on DHR. Barclays lifted their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Robert W. Baird lifted their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Citigroup lifted their target price on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Trading Down 1.8 %

Shares of DHR stock opened at $245.82 on Wednesday. The firm has a market capitalization of $182.04 billion, a P/E ratio of 41.66, a P/E/G ratio of 4.24 and a beta of 0.83. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock’s fifty day simple moving average is $248.94 and its 200 day simple moving average is $230.88.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.48% and a net margin of 16.78%. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.36 EPS. As a group, sell-side analysts predict that Danaher will post 7.62 EPS for the current fiscal year.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Insiders sold 84,132 shares of company stock valued at $21,022,795 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Petredis Investment Advisors LLC increased its holdings in Danaher by 1.9% during the 1st quarter. Petredis Investment Advisors LLC now owns 10,710 shares of the conglomerate’s stock worth $2,675,000 after purchasing an additional 204 shares in the last quarter. Caliber Wealth Management LLC increased its holdings in Danaher by 4.1% during the 1st quarter. Caliber Wealth Management LLC now owns 10,243 shares of the conglomerate’s stock worth $2,558,000 after purchasing an additional 401 shares in the last quarter. Bogart Wealth LLC increased its holdings in Danaher by 25.9% during the 1st quarter. Bogart Wealth LLC now owns 32,423 shares of the conglomerate’s stock worth $8,097,000 after purchasing an additional 6,677 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Danaher by 12.2% during the 1st quarter. Lindbrook Capital LLC now owns 5,423 shares of the conglomerate’s stock worth $1,354,000 after purchasing an additional 591 shares in the last quarter. Finally, Osborne Partners Capital Management LLC increased its holdings in Danaher by 2.0% during the 1st quarter. Osborne Partners Capital Management LLC now owns 91,322 shares of the conglomerate’s stock worth $22,805,000 after purchasing an additional 1,768 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.